An anonymous director reports
AETERNA ZENTARIS RECEIVES EXTENSION FROM NASDAQ TO SATISFY CONTINUING LISTING REQUIREMENTS
Aeterna Zentaris Inc. has received a positive decision from the staff of the listing qualifications department of the Nasdaq Stock Market, granting the company's request for an extension through Oct. 5, 2020, to achieve compliance with the minimum $2.5-million stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The staff's determination followed the company's submission of its compliance plan for the staff's consideration on May 26, 2020.
The company is pursuing a number of initiatives to increase stockholders' equity, the completion of which are expected to enable it to achieve compliance with the minimum stockholders' equity requirement by no later than Oct. 5, 2020, and to thereafter maintain compliance with the listing requirements.
About Aeterna Zentaris Inc.
Aeterna is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.